<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00964132</url>
  </required_header>
  <id_info>
    <org_study_id>194204-203</org_study_id>
    <nct_id>NCT00964132</nct_id>
  </id_info>
  <brief_title>Oral NRX 194204 Study in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)</brief_title>
  <official_title>A Multiple-Center, Open-Label, Study of the Safety and Efficacy of Oral NRX 194204 Capsule Administered Daily for a Minimum of 4 Weeks in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NuRx Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NuRx Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether NRX 194204 is effective in the treatment of&#xD;
      advanced Non-Small Cell Lung Cancer (NSCLC).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Numerous studies in pre-clinical models and in human clinical trials have clearly established&#xD;
      the potential for the use of rexinoids in the treatment and prevention of cancer. NRX 194204,&#xD;
      a second generation rexinoid, is a highly potent and specific activator of RXRs. Because NRX&#xD;
      194204 is significantly more selective for the RXRs relative to the RARs than a first&#xD;
      generation approved drug, it is associated with fewer adverse events in clinical use. This&#xD;
      study seeks to investigate NRX 194204 monotherapy in patients who have failed any 2 prior&#xD;
      therapies.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>March 2009</start_date>
  <completion_date type="Anticipated">June 2010</completion_date>
  <primary_completion_date type="Anticipated">March 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall objective tumor response rate</measure>
    <time_frame>7 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>7 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>7 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall safety and toxicity of NRX 194204 in NSCLC patients</measure>
    <time_frame>7 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Non-small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>NRX194204</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NRX194204</intervention_name>
    <description>Once Daily, Oral</description>
    <arm_group_label>NRX194204</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female, age ≥ 18 years&#xD;
&#xD;
          -  Histologically confirmed advanced stage III or IV NSCLC that is recurrent or has&#xD;
             progressed after treatment. Failure on at least 2 NSCLC treatment regimens&#xD;
&#xD;
          -  Uni-dimensionally measurable NSCLC defined as at least one lesion that can be measured&#xD;
             in at least one dimension (longest diameter to be recorded) as ≥ 2cm with conventional&#xD;
             techniques or as ≥ 1cm on spiral CT scan.&#xD;
&#xD;
          -  Patients are eligible if disease free from previous malignancies, other than a&#xD;
             previous NSCLC, for greater than two years. Patients with a history of prior basal&#xD;
             cell carcinoma of the skin or pre-invasive carcinoma of the cervix are not excluded.&#xD;
&#xD;
          -  Karnofsky performance status ≥ 60 (Attachment 14.4) or ECOG performance status 0-2&#xD;
&#xD;
          -  Life expectancy &gt; 12 weeks.&#xD;
&#xD;
          -  Able to swallow capsule form of the drug.&#xD;
&#xD;
          -  Hematology:&#xD;
&#xD;
               -  Hemoglobin &gt; 8.5 g/dl;&#xD;
&#xD;
               -  Platelets &gt; 100,000 cells/mm3;&#xD;
&#xD;
               -  Neutrophils &gt; 1500 cells/mm3;&#xD;
&#xD;
               -  PT and PTT within normal limits, except for patients receiving Coumadin for&#xD;
                  thromboembolic prophylaxis only, in whom INR of less than 2 will be allowable.&#xD;
&#xD;
          -  Biochemistry:&#xD;
&#xD;
               -  Total bilirubin &lt; 1.5 x ULN;&#xD;
&#xD;
               -  AST/ALT &lt; 3.0 x ULN;&#xD;
&#xD;
               -  Serum creatinine &lt; 2.0 mg/dl;&#xD;
&#xD;
               -  Serum calcium &lt; 11.5 mg/dl;&#xD;
&#xD;
               -  Fasting serum triglycerides &lt; 2.5 x ULN.&#xD;
&#xD;
          -  Negative urine pregnancy test for women of child-bearing potential at screening and on&#xD;
             Day 1, and agreement by both women and men of reproductive potential to use two&#xD;
             reliable forms of contraception during therapy and for 1 month following&#xD;
             discontinuation of therapy unless abstinence is the chosen birth control method.&#xD;
&#xD;
          -  Able to follow study instructions, accessible for treatment and follow-up, and likely&#xD;
             to complete all study requirements.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Significant medical history or unstable medical condition (congestive heart failure,&#xD;
             recent myocardial infarction within 3 months, unstable angina, active systemic&#xD;
             infection, uncontrolled hypertension). Patients with controlled diabetes will be&#xD;
             allowed.&#xD;
&#xD;
          -  Prior treatment with bexarotene (Targretin) or NRX 194204.&#xD;
&#xD;
          -  Current enrollment in an investigational drug or device study or participation in such&#xD;
             a study within 21 days of entry into this study.&#xD;
&#xD;
          -  Known sensitivity to any of the ingredients in the study medication.&#xD;
&#xD;
          -  Known HIV-positive patients.&#xD;
&#xD;
          -  Females who are pregnant, nursing, or planning a pregnancy.&#xD;
&#xD;
          -  Major surgery within previous 4 weeks; large field radiation therapy (&gt; 25% of the&#xD;
             patient's total marrow) or chemotherapy (including investigational agents or&#xD;
             participation in another clinical study) within previous 3 weeks; mitomycin C or&#xD;
             nitrosoureas within 6 weeks. In all instances, patients must have fully recovered from&#xD;
             acute toxicities related to prior therapies.&#xD;
&#xD;
          -  Systemic retinoid therapy, or Vitamin A at dosages &gt; 15,000 IU per day, during&#xD;
             previous 4 weeks.&#xD;
&#xD;
          -  Patients with a history of pancreatitis or at significant risk of developing&#xD;
             pancreatitis (e.g., uncontrolled hyperlipidemia, excessive alcohol consumption,&#xD;
             uncontrolled diabetes mellitus, and medications known to increase triglyceride levels&#xD;
             or to be associated with pancreatic toxicity).&#xD;
&#xD;
          -  Primary brain tumors, active brain metastasis including progression from last scan or&#xD;
             evidence of cerebral edema, or clinical symptoms of brain metastasis.&#xD;
&#xD;
          -  Condition or situation which, in the investigator's opinion, may put patient at&#xD;
             significant risk, may confound the study results, or may interfere significantly with&#xD;
             patient's participation in the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Dr. Pandit</name>
      <address>
        <city>Fountain Valley</city>
        <state>California</state>
        <zip>92708</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCSD Moores Cancer Center</name>
      <address>
        <city>La Jolla,</city>
        <state>California</state>
        <zip>92093-0698</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>USC Norris Comprehensive Cancer Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dartmouth Hitchcock Medical Center</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Somerset Oncology Hematology Associates</name>
      <address>
        <city>Somerville</city>
        <state>New Jersey</state>
        <zip>08876</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Swedish Cancer Institute</name>
      <address>
        <city>Seattle,</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2009</verification_date>
  <study_first_submitted>August 20, 2009</study_first_submitted>
  <study_first_submitted_qc>August 21, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 24, 2009</study_first_posted>
  <last_update_submitted>September 2, 2009</last_update_submitted>
  <last_update_submitted_qc>September 2, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 3, 2009</last_update_posted>
  <responsible_party>
    <name_title>Roshantha A. Chandraratna, PhD, MBA, Chief Scientific Officer</name_title>
    <organization>NuRx Pharmaceuticals</organization>
  </responsible_party>
  <keyword>Non-Small Cell Lung Cancer</keyword>
  <keyword>NSCLC</keyword>
  <keyword>Rexinoid</keyword>
  <keyword>NRX194204</keyword>
  <keyword>Lung Cancer</keyword>
  <keyword>RXR</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

